This company has been acquired
Jounce Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Jounce Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04
Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13
Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jounce Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2022 | 82 | -51 | -30 | -29 | N/A |
| 9/30/2022 | N/A | -132 | -117 | -116 | N/A |
| 6/30/2022 | N/A | -131 | -82 | -82 | N/A |
| 3/31/2022 | 25 | -102 | -83 | -83 | N/A |
| 12/31/2021 | 27 | -91 | -84 | -83 | N/A |
| 9/30/2021 | 89 | -25 | -16 | -16 | N/A |
| 6/30/2021 | 89 | -20 | -41 | -41 | N/A |
| 3/31/2021 | 64 | -44 | -38 | -38 | N/A |
| 12/31/2020 | 62 | -44 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -102 | -86 | -86 | N/A |
| 6/30/2020 | 119 | 22 | -31 | -31 | N/A |
| 3/31/2020 | 137 | 43 | -31 | -30 | N/A |
| 12/31/2019 | 148 | 57 | -31 | -30 | N/A |
| 9/30/2019 | 168 | 77 | -32 | -31 | N/A |
| 6/30/2019 | 63 | -29 | -83 | -82 | N/A |
| 3/31/2019 | 65 | -27 | -67 | -66 | N/A |
| 12/31/2018 | 65 | -27 | -65 | -64 | N/A |
| 9/30/2018 | 58 | -35 | -71 | -68 | N/A |
| 6/30/2018 | 62 | -31 | -79 | -75 | N/A |
| 3/31/2018 | 63 | -30 | -103 | -95 | N/A |
| 12/31/2017 | 72 | -17 | -106 | -91 | N/A |
| 9/30/2017 | 79 | -5 | -93 | -79 | N/A |
| 6/30/2017 | 78 | -1 | 147 | 161 | N/A |
| 3/31/2017 | 57 | -11 | 165 | 174 | N/A |
| 12/31/2016 | 37 | -23 | 177 | 180 | N/A |
| 9/30/2016 | 17 | -38 | N/A | 184 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if JNCE's forecast earnings growth is above the savings rate (2.1%).
Earnings vs Market: Insufficient data to determine if JNCE's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if JNCE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if JNCE's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if JNCE's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JNCE's Return on Equity is forecast to be high in 3 years time